TrialESMO open2024

Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study.

C Fong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.